SHARE THIS PAGE:
Advanced Science (Xu, J., et al.) 08.31.2023 published “Developing a Blood Cell-Based Diagnostic Test for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Using Peripheral Blood Mononuclear Cells.” In this study, researchers utilized a […]
The Parasites & Vectors Journal (Arahirwa V., et al.) 08.24.2023, published “Impact of the COVID-19 pandemic on delays in diagnosis and treatment of tick-borne diseases endemic to southeastern USA.” This article talks about how the COVID-19 pandemic affected the diagnosis and treatment of diseases transmitted by ticks, like Lyme disease.
The COVID-19 pandemic caused delays in diagnosing and treating various medical conditions. The impact this has on tick-borne diseases, which can have symptoms similar to COVID-19, hasn’t been well understood. This study looked at patients with suspected tick-borne diseases before and after COVID-19 to see if there were delays in diagnosing and treating these diseases during the pandemic.
JAMA (Raison, C.L., eta al.) 8.31.2023 published “Single-Dose Psilocybin Treatment for Major Depressive Disorder – A Randomized Clinical Trial.” In this study, researchers evaluated single dose psilocybin for its antidepressant […]
EXPECTATIONS: The recent Bloomberg article on the upcoming Lyme disease vaccine was not a surprise but was certainly a disappointment to the Lyme community and the Lyme Disease Association Inc. (LDA). The reporter spent time tracking me down to do an interview, as she indicated to me, many in the Lyme Community had suggested to her that I should be interviewed, probably due to the LDA’s involvement in the Lyme scene during the prior vaccine withdrawal.
LDA INVOLVEMENT IN EARLY VACCINE: At the time the first Lyme OspA vaccine, LymeRix®, was receiving FDA approval, with the most provisos− according to the chairperson−the LDA was already more than a decade into educating about and providing research funds for Lyme disease. As LDA president, I was educating in NJ and elsewhere. The prevailing questions and comments were always the same: talk and questions about the vaccine− problems that many people said they/acquaintances were experiencing and attributing to the vaccine.
The People’s Pharmacy writer, Joe Graedon, published 08.21. 2023 “Why Is Alpha-Gal Allergy So Misunderstood and Misdiagnosed?” In this article, Graedon explains the multiple challenges of diagnosis of Alpha-gal allergy […]
The Cureus Journal (Aydin, Y., et al.) 07.07.2023, published “Severe Anaplasmosis With Multiorgan Involvement in a Rheumatoid Arthritis Patient.” This case report is of a 66-year-old woman from Connecticut with severe anaplasmosis. Anaplasmosis is an emerging tick-borne disease caused by the bacterium Anaplasma phagocytophilum, primarily transmitted through the bite of a black-legged tick, including Ixodes scapularis and Ixodes pacificus. Anaplasmosis is more common in certain US regions, including the upper Midwest, Northeast, and mid-Atlantic states, and most reported in Connecticut.
Bloomberg released an article “Lyme Disease Has Exploded, and a New Vaccine Is (Almost) Here” on 8.24.2023, written by Kristen V Brown and Nacha Cattan. The article talks about Lyme disease and a potential new vaccine. In recent times, Lyme disease has become the most common vector-borne illness in the US. Due to this increasing prevalence of this disease, there is more urgency to develop a vaccine. Currently, there is only a vaccine available for dogs against Lyme disease.
The Frontiers in Psychiatry Journal (Offutt, A. & Breitschwerdt, E. B.) 08.18.2023, published “Case report: Substantial improvement of autism spectrum disorder in a child with learning disabilities in conjunction with treatment for poly-microbial vector borne infections.” The case article describes a boy diagnosed with autism spectrum disorder (ASD) and learning disabilities who showed improvement in his cognitive and neurobehavioral symptoms after receiving antimicrobial treatment for poly-microbial vector-borne infections.
In a breaking Fierce Biotech news article, 08.22.2023, Pfizer announced that the number of people enrolled in the phase 3 clinical trial for the Lyme vaccine (VLA15) will be significantly […]
Journal of Medical Entomology (Schulze, T.L., et al.) 08.04.2023 published an open access article, “Community-based integrated tick management programs: cost and feasibility scenarios.” In this article, researchers explore the cost […]
LDA Doctor Referral System © Terms & Conditions and Guidelines
Save this Information for Your Records:
About LDA DOCTOR REFERRAL SYSTEM ©
Welcome to the Lyme Disease Association’s LDA Doctor Referral System ©. LDA made updates and enhancements to its prior system and has launched a new site to provide patients with information about doctors, other practitioners, testing labs, and pharmacies that are knowledgeable about chronic Lyme disease and often about many other tick-borne diseases (TBD). Many of the doctors listed are often referred to as Lyme Literate Physicians/Doctors (LLMD). Tens of thousands of patients have successfully used the prior LDA system to locate Lyme and TBD resources.
Terms & Conditions and Guidelines
Because there is a negative political climate surrounding Lyme disease, many LLMDs do not want their names posted outright on the internet. LDA has tried to balance the doctors’ wishes with patients’ need to find a doctor. This new system is a result of that compromise and therefore:
Because of the limited number of physicians treating chronic Lyme disease nationwide, some states, and in some instances, entire regions, may not have any treating physicians who follow flexible treating approaches such as those in the International Lyme & Associated Diseases Society (ILADS) Guidelines, Evidence Assessments and Guideline Recommendations in Lyme Disease: The Clinical Management of Known Tick Bites, Erythema Migrans Rashes and Persistent Disease. In the event that the LDA Doctor Referral System © contains no Lyme or TBD resource listings in a given area, the closest possible option(s) will populate based on the location entered and specaialty/ies selected. The LDA appreciates any changes in provider information that you may find and make us aware of so we can investigate.